Pfizer’s COVID-19 vaccine booster for children under age 5 was 80.3% effective and well tolerated in a clinical trial involving 1,678 children who received the 3-microgram dose at least two months after the primary vaccine series at a time when the omicron variant was predominating, the company announced today. Pfizer expects to submit the data to the Food and Drug Administration this week for the company’s emergency use application.

Related News Articles

Headline
The Centers for Disease Control and Prevention today released updated guidance for clinicians treating COVID-19 in patients who received the Pfizer COVID-19…
Headline
The Centers for Disease Control and Prevention yesterday recommended children age 5-11 receive a booster dose five months after completing the Pfizer COVID-19…
Headline
U.S. residents can order online eight more free at-home tests for COVID-19, the White House announced yesterday. People who have difficulty accessing the…
Headline
The Food and Drug Administration today authorized a single Pfizer COVID-19 booster dose for children aged 5-11 who completed the Pfizer vaccine primary series…
Headline
The Food and Drug Administration yesterday approved using Olumiant (baricitinib) to treat COVID-19 in hospitalized adults requiring supplemental oxygen,…
Headline
The Food and Drug Administration last week extended to 24 months the shelf life for certain lots of refrigerated bamlanivimab. The combination monoclonal…